I lead Digital Health for BioPharmaceuticals R&D. In Digital Health R&D, we are transforming R&D through digital, data and AI to deliver new digital health solutions to improve outcomes and experience for patients, and to partner with colleagues globally to reimagine healthcare delivery.  

I lead a diverse team focusing on accelerating and differentiating our clinical development programmes through digital health solutions and on the development of digital therapeutics. A recent example is the implementation and scale up of Unify, our new clinical study support platform which is now part of several of our trials around the world. Unify is enabling us to improve remote patient data collection, as well as supporting clinical trial accessibility, diversity and retention. We also work actively with the R&D therapy area teams to explore approaches that can combine our innovative new treatments with evidence-based digital health solutions, such as digital biomarkers, digital diagnostics and digital therapeutics.

A chemist by training, I have been part of the pharmaceutical industry for over 25 years. I have been at AstraZeneca for over 20 years in various roles across R&D and Operations, including as Founder and Head of the Intelligent Pharmaceuticals group, Project Director in Chemistry, Manufacturing and Controls (CMC) and Project Lead roles across different therapy areas.


Throughout my time at AstraZeneca, I’ve been passionate about clinical innovation. I firmly believe we are moving towards a future where digital solutions have the potential to robustly improve medication use, collect data directly from patients to support self-management, and improve clinical outcomes.

Matt Bonam Head of Digital Health, BioPharmaceuticals R&D

Drug Information Association (DIA) Global Annual Meeting 2021

Realizing the Value of Digital Biomarkers Across the Product Lifecycle

Clinical Trials Europe 2021

Decentralised trials. Does the hype meet reality


Head of Digital Health, BioPharmaceuticals R&D

2015 – 2018

Founder and Head of the Intelligent Pharmaceuticals group, responsible for the successful delivery of over 45 testing programmes and helping establish the foundations for scaling the use of digital solutions to deliver patient centric trials and for developing digital therapeutics


Project Director in CMC across all therapy areas, leading successful delivery of a number of Phase 3 programmes and innovating in early phase programmes through the use of exploratory investigational new drugs

2011 – 2013

Project Lead for a Microbial Sciences (infection) portfolio, leading the team to assess development options linked to potential for commercial differentiation

Veeva ID: Z4-35299
Date of preparation: July 2021